CAR-T is expensive. CMS is still figuring things out
The FDA approved the first CAR-T treatments, Novartis’s Kymriah and Gilead’s Yescarta, in 2017, but CMS is still struggling to find a way to pay for these cutting-edge, costly therapies.
The missteps have been many: The agency still doesn’t have a uniform policy for covering these therapies; it's balked at shelling out extra cash to make hospitals whole; and it was forced in July 2018 to walk away from a closely watched deal to pay for Kymriah only when it works as intended.
CMS Administrator Seems Verma told STAT's Nicholas Florko that she, too, is frustrated by the government’s inability to figure out how to pay for these treatments, and she warns it could take years before things are finally smoothed out. “It’s a great microcosm into the complexities of government price setting,” she told STAT.
Read more.
The missteps have been many: The agency still doesn’t have a uniform policy for covering these therapies; it's balked at shelling out extra cash to make hospitals whole; and it was forced in July 2018 to walk away from a closely watched deal to pay for Kymriah only when it works as intended.
CMS Administrator Seems Verma told STAT's Nicholas Florko that she, too, is frustrated by the government’s inability to figure out how to pay for these treatments, and she warns it could take years before things are finally smoothed out. “It’s a great microcosm into the complexities of government price setting,” she told STAT.
Read more.
No hay comentarios:
Publicar un comentario